Hybridoma cell strain, monoclonal antibody and application
By providing monoclonal antibodies and hybridoma cell lines that can specifically recognize chlorofluoropyacetic acid and isoctyl chlorofluoropyacetic acid, the complex and cost-effectiveness of existing detection methods is solved, and rapid and sensitive detection is achieved Effect.
Patent Information
- Application Number
- CN202411154651.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-21
AI Technical Summary
The existing residue detection methods of chlorofluoropyacetic acid and isoctyl chlorofluoropyacetic acid require professional equipment and complex operations, are costly, and lack monoclonal antibodies that can specifically recognize these two substances at the same time.
A hybridoma cell line 11D8 and monoclonal antibodies secreted from it were provided, which specifically recognize chlorofluoropyacetic acid and isoctyl chlorofluoropyacetic acid for indirect competition for ELISA detection, simplifying the detection process.
Fast, simple and highly sensitive detection is achieved, cost-effective, and provides a method suitable for on-site detection, meeting the high-throughput analysis needs for these two herbicide residues.
Smart Images

Figure CN118909960A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of food safety immunoassay, and in particular relates to a hybridoma cell line, a monoclonal antibody and applications. Background Art
[0002] Flupyralid and isooctyl flupyralid are pyridinyloxyacetic acid herbicides, which have systemic transmissibility and typical hormone herbicide reactions. They are produced in large quantities and widely used. After application, isooctyl flupyralid can be rapidly hydrolyzed into its parent substance, flupyralid, in the plant body.
[0003] At present, the method about the residual detection of fluroxypyra and fluroxypyra isooctyl is mainly concentrated in the instrument detection aspect, such as high performance liquid chromatography (LC), high performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS), gas chromatography (GC), gas chromatography-tandem mass spectrometry (GC-MS / MS) etc., but these methods need professional operator, large-scale instrument and equipment, complicated sample pretreatment and time-consuming analytical process, and the detection cost is high, which is unfavorable for the detection of fluroxypyra and fluroxypyra isooctyl is now. Immunoassay method has the advantages of fast, simple, real-time, easy to carry out on-site detection, simple sample pretreatment, high sensitivity, strong selectivity, suitable for high-throughput analysis, and can significantly reduce the detection cost due to its specific recognition effect on antigen and antibody. However, there is a lack of monoclonal antibodies that can specifically identify fluroxypyra and fluroxypyra isooctyl simultaneously. Summary of the invention
[0004] The purpose of the present invention is to provide a hybridoma cell line, a monoclonal antibody and application. The monoclonal antibody of the present invention can specifically recognize a broad spectrum of clofopyralid and clofopyralid isooctyl ester at the same time.
[0005] The invention provides a hybridoma cell strain, which is named as 11D8 and deposited in the General Microbiological Center of China Microbiological Culture Collection Administration, with a deposit number of CGMCC No.45937.
[0006] The present invention also provides the use of the hybridoma cell line described in the above scheme in preparing a monoclonal antibody that specifically recognizes both lofluanid and lofluanid ethyl ester.
[0007] The present invention also provides a monoclonal antibody, which is secreted and produced by the hybridoma cell line or its successive cell line described in the above scheme.
[0008] The present invention also provides a monoclonal antibody, the amino acid sequence of the heavy chain variable region of the monoclonal antibody comprises: the heavy chain variable region CDR1 as shown in SEQ ID NO.1, the heavy chain variable region CDR2 as shown in SEQ ID NO.2 and the heavy chain variable region CDR3 as shown in SEQ ID NO.3; the amino acid sequence of the light chain variable region of the monoclonal antibody comprises: the light chain variable region CDR1 as shown in SEQ ID NO.4, the light chain variable region CDR2 as shown in SEQ ID NO.5 and the light chain variable region CDR3 as shown in SEQ ID NO.6.
[0009] Preferably, the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO.7; and the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO.8.
[0010] The present invention also provides a gene encoding the monoclonal antibody described in the above scheme, wherein the nucleotide sequence of the heavy chain variable region of the gene encoding the monoclonal antibody comprises: a heavy chain variable region CDR1 as shown in SEQ ID NO.9, a heavy chain variable region CDR2 as shown in SEQ ID NO.10, and a heavy chain variable region CDR3 as shown in SEQ ID NO.11; the nucleotide sequence of the light chain variable region of the gene encoding the monoclonal antibody comprises: a light chain variable region CDR1 as shown in SEQ ID NO.12, a light chain variable region CDR2 as shown in SEQ ID NO.13, and a light chain variable region CDR3 as shown in SEQ ID NO.14.
[0011] Preferably, the gene sequence of the heavy chain variable region of the gene encoding the monoclonal antibody is shown as SEQ ID NO.15; the gene sequence of the light chain variable region of the gene encoding the monoclonal antibody is shown as SEQ ID NO.16.
[0012] The present invention also provides a kit or a test strip, comprising the monoclonal antibody described in the above scheme.
[0013] The present invention also provides the use of the hybridoma cell line, the monoclonal antibody, the encoding gene or the kit or test strip described in the above scheme in detecting clofopyralid and / or clofopyralid isooctyl ester.
[0014] The present invention also provides a method for detecting clofopyralid and / or clofopyralid isooctyl by indirect competitive ELISA, comprising the following steps:
[0015] The sample to be tested was used as the coating antigen and the monoclonal antibody described in the above scheme was used as the primary antibody to perform indirect competitive ELISA detection.
[0016] The invention provides a hybridoma cell strain, which is named 11D8 and deposited in the General Microbiology Center of China National Committee for Microbiological Culture Collection, with a deposit number of CGMCC No. 45937. The monoclonal antibody secreted by the hybridoma cell strain of the invention can specifically identify lofluroxyacetic acid and lofluroxyacetic acid isooctyl ester at the same time, and has good detection sensitivity to lofluroxyacetic acid and lofluroxyacetic acid isooctyl ester; the detection of the residual amount of lofluroxyacetic acid and lofluroxyacetic acid isooctyl ester in food can be realized, and a new means is provided for establishing a rapid, simple, inexpensive, sensitive and specific detection method for lofluroxyacetic acid and lofluroxyacetic acid isooctyl ester.
[0017] Biological Deposit Description
[0018] Mouse hybridoma cell line 11D8, the depository unit is: General Microbiology Center of China Culture Collection Administration, the deposit address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, the deposit number is: CGMCC No.45937, and the deposit date is: June 4, 2024. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0020] Figure 1 It is the MALDI-TOF-MS spectrum of the ovalbumin (OVA) standard and the molar ratio (coupling ratio) of OVA to chloroquine and chloroquine ethyl ester hapten B of 1:30;
[0021] Figure 2 It is the MALDI-TOF-MS spectrum of the ovalbumin (OVA) standard and the molar ratio (coupling ratio) of OVA to chloroquine and chloroquine ethyl ester hapten B of 1:40;
[0022] Figure 3 It is the MALDI-TOF-MS spectrum of the ovalbumin (OVA) standard and the molar ratio (coupling ratio) of OVA to clofopyralid and clofopyralid isooctyl ester hapten B of 1:50;
[0023] Figure 4 is the MALDI-TOF-MS spectrum of ovalbumin (OVA) standard;
[0024] Figure 5The MALDI-TOF-MS spectra of bovine serum albumin (BSA) standard and the molar ratio (coupling ratio) of BSA to chloroquine and chloroquine ethyl ester hapten B are 1:30 respectively;
[0025] Figure 6 The MALDI-TOF-MS spectra of bovine serum albumin (BSA) standard and the molar ratio (coupling ratio) of BSA to chloroquine and chloroquine ethyl ester hapten B are 1:40 respectively;
[0026] Figure 7 The MALDI-TOF-MS spectra of bovine serum albumin (BSA) standard and the molar ratio (coupling ratio) of BSA to clofopyralid and clofopyralid isooctyl ester hapten B are 1:50 respectively;
[0027] Figure 8 is the MALDI-TOF-MS spectrum of bovine serum albumin (BSA) standard;
[0028] Figures 1 to 8 The horizontal axis is m / z (ratio of proton number / charge number, mass-to-charge ratio), and the vertical axis is signal intensity (arbitrary unit);
[0029] Fig. 9 The results of the subtype detection of monoclonal antibodies produced by hybridoma cell line 11D8;
[0030] Fig.10 This is the standard curve of the broad-spectrum specific monoclonal antibody produced by hybridoma cell line 11D8. DETAILED DESCRIPTION
[0031] The invention provides a hybridoma cell strain, which is named as 11D8 and deposited in the General Microbiological Center of China Microbiological Culture Collection Administration, with a deposit number of CGMCC No.45937.
[0032] The hybridoma cell line of the invention can secrete a monoclonal antibody capable of simultaneously recognizing lofluanid and lofluanid ethyl ester.
[0033] In the present invention, fluroxypyr, also known as fluroxypyr, fluroxypyr, fluroxypyr, dundun, has a chemical name of 4-amino-3,5-dichloro-6-fluoro-pyridine-2-oxyacetic acid, a CAS number of 69377-81-7, a molecular formula of C7H5O3N2FCL2, a relative molecular weight of 255, and a chemical structural formula as shown in Formula I:
[0034]
[0035] In the present invention, flurpyrrolidone isooctyl ester, the chemical name is 1-methylheptyl ester, ((4-amino-3,5-dichloro-6-fluoro-2-pyridinyl)oxy)-acetic acid 1-methylheptyl ester or flurpyrrolidone methylheptyl ether, CAS No. 81406-37-3, molecular formula C 15 H 21 Cl2FN2O3, relative molecular weight is 367.24, chemical structure is shown in formula II:
[0036]
[0037] In the present invention, the hybridoma cell line is preferably prepared by the following method:
[0038] The method comprises the following steps: using cloflupyr as a hapten; coupling the hapten with a carrier protein to obtain a complete antigen; mixing the complete antigen with a Freund's adjuvant for emulsification, subcutaneously immunizing mice, and screening mice with good immune effects; fusing spleen cells of the mice with good immune effects with myeloma cells to obtain a hybridoma cell line.
[0039] The present invention uses fluroxypyrazone as a hapten (hereinafter referred to as hapten A), which has a structure shown in formula A:
[0040]
[0041] In the present invention, as a hapten, it must have an active group or an active group with a linker group, and the active group is preferably a carboxyl group, an amino group, a hydroxyl group or an ester group, and the selected clofopyralid structure itself has a carboxyl structure.
[0042] The present invention couples the hapten with a carrier protein to obtain a complete antigen. In the present invention, the carrier protein is preferably bovine serum albumin or ovalbumin.
[0043] In the present invention, the clofopyralid is preferably linked to the amino group of the carrier protein by the activated ester method. After the reaction is completed, the complete antigen and the uncoupled small molecule hapten are separated by dialysis; the complete antigen is identified by the MALDI-TOF-MS method.
[0044] In the present invention, the -COOH on the formula A is activated by the activated ester method with N-hydroxysuccinimide (NHS) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) under the action of N,N-dimethylformamide to form an activated intermediate of hapten A, so as to facilitate coupling with the carrier protein and improve the success rate of coupling; the chemical structure of the activated intermediate of hapten A is shown in formula B:
[0045]
[0046] In the present invention, when the carrier protein is OVA, the complete antigen of fluroxypyraclostrobin and fluroxypyraclostrobin has a structure shown in formula C1 (referred to as fluroxypyraclostrobin and fluroxypyraclostrobin complete antigen C1); when the carrier protein is BSA, the fluroxypyraclostrobin and fluroxypyraclostrobin has a structure shown in formula C2 (referred to as fluroxypyraclostrobin and fluroxypyraclostrobin complete antigen C2):
[0047]
[0048] In the present invention, the molar ratio of the activated intermediate of hapten A to the carrier protein is preferably (10-80):1, more preferably (30-60):1. In the present invention, the buffer preferably includes carbonate buffer, phosphate buffer (PBS buffer), borate buffer or 4-hydroxyethylpiperazineethanesulfonic acid buffer, more preferably PBS buffer; the buffer is used as a solvent, and its amount can ensure the smooth progress of the coupling reaction, and the present invention does not make any special restrictions on this. In the present invention, the activated intermediate of hapten A, the carrier protein and the buffer are preferably mixed in the following manner: the carrier protein is mixed with the buffer to obtain a buffer solution of the carrier protein, and then the activated intermediate of hapten A is added; the pH value of the buffer solution of the carrier protein is preferably 5-9, more preferably 7.4. In the present invention, the temperature of the coupling reaction is preferably 0-50°C, more preferably 4-25°C; the time is preferably 4-36h, more preferably 4-12h; the coupling reaction is preferably carried out under stirring conditions. After the coupling reaction, the present invention preferably dialyzes the obtained product system to obtain the complete antigen of fluroxypyr and fluroxypyr ethyl ester having the structure shown in formula C. In an embodiment of the present invention, the coupling reaction is carried out using PBS buffer as a solvent, and the dialysate used for dialysis after the coupling reaction is preferably PBS buffer, and the pH value of the PBS buffer is preferably 7 to 10, more preferably 7.4; the concentration is preferably 0.01 to 0.2 mol / L, more preferably 0.01 mol / L; the number of dialysis is preferably 5 to 7 times, more preferably 6 times; the time of each dialysis is preferably 3 to 5 hours, more preferably 4 hours.
[0049] After obtaining the complete antigen, the present invention mixes the complete antigen with Freund's complete adjuvant for emulsification, performs subcutaneous immunization on mice, and screens mice with good immune effects. In the specific implementation process of the present invention, the immunogen is mixed and emulsified with complete Freund's adjuvant for the first immunization, and the immunogen is mixed and emulsified with incomplete Freund's adjuvant for multiple booster immunizations, and finally the immunogen is diluted with PBS and injected intraperitoneally for sprint immunization.
[0050] In the specific implementation process of the present invention, the mouse is preferably a BALB / c mouse of 6 to 8 weeks old. After the immunogen is completely emulsified with Freund's complete adjuvant, the mouse is immunized by multiple subcutaneous injections. Freund's complete adjuvant is used for the first immunization, Freund's incomplete adjuvant is used for the booster immunization, and no adjuvant is used for the sprint immunization. After mixing evenly with physiological saline, it is directly injected intraperitoneally; the interval between each immunization is two weeks. After the third immunization, blood is collected at intervals of one week to detect serum titer and inhibition.
[0051] After obtaining mice with good immune effects, the present invention fuses spleen cells of the mice with good immune effects with myeloma cells to obtain hybridoma cell lines.
[0052] In the specific implementation of the present invention, the method for fusing the spleen cells and myeloma cells is preferably the polyethylene glycol (PEG 2000) method; after the fusion, the cells are cultured in HAT medium, the positive cell wells are detected by indirect ELISA, and the inhibitory effect of the positive cell wells is further determined by indirect competitive ELISA. The positive cell wells with the best inhibition are subcloned three times by limiting dilution method, and finally the hybridoma cell line 11D8 is obtained by screening.
[0053] After obtaining the hybridoma cell strain, the present invention preferably further comprises identifying the hybridoma cell strain; the identification method preferably comprises: determining antibody subtype, IC 50 value, cross-reaction rate and affinity; the antibody subtype is preferably determined using Sigma's mouse monoclonal antibody typing test strips; the IC 50 The determination of the affinity, cross-reaction rate and affinity is preferably performed by indirect competitive ELISA method (ic-ELISA method).
[0054] The present invention also provides an antibody against both fluroxypyra and fluroxypyrazone-2-ethylhexyl, which is prepared from the complete antigens of fluroxypyra and fluroxypyrazone-2-ethylhexyl. In the present invention, the anti-fluroxypyrazone antibody is preferably anti-fluroxypyrazone serum.
[0055] A host animal is immunized with complete antigens of fluroxypyraclostrobin and fluroxypyraclostrobin, spleen cells are separated from the host animal, the spleen cells are fused with SP2 / 0 tumor cells in vitro, hybridoma cell lines that can secrete antibodies against fluroxypyraclostrobin and fluroxypyraclostrobin, and monoclonal antibodies against fluroxypyraclostrobin and fluroxypyraclostrobin are prepared based on the hybridoma cell lines; or, mRNA transcribed from B lymphocytes in the blood of the host animal is extracted, reversely transcribed into cDNA, and monoclonal antibodies against fluroxypyraclostrobin and fluroxypyraclostrobin are screened through a phage or yeast antibody expression library constructed by bioengineering technology.
[0056] The present invention also provides the use of the hybridoma cell line described in the above scheme in preparing a monoclonal antibody that specifically recognizes both lofluanid and lofluanid ethyl ester.
[0057] The present invention also provides a monoclonal antibody, which is secreted by the hybridoma cell line or its successive cell line described in the above scheme. The monoclonal antibody secreted by the hybridoma cell line 11D8 of the present invention exhibits excellent affinity and sensitivity to clofopyralid and clofopyralid isooctyl ester, and the IC 50 The values were 1.95 ng / mL and 1.36 ng / mL respectively.
[0058] The present invention also provides a monoclonal antibody, the amino acid sequence of the heavy chain variable region of the monoclonal antibody comprises: the heavy chain variable region CDR1 as shown in SEQ ID NO.1, the heavy chain variable region CDR2 as shown in SEQ ID NO.2 and the heavy chain variable region CDR3 as shown in SEQ ID NO.3; the amino acid sequence of the light chain variable region of the monoclonal antibody comprises: the light chain variable region CDR1 as shown in SEQ ID NO.4, the light chain variable region CDR2 as shown in SEQ ID NO.5 and the light chain variable region CDR3 as shown in SEQ ID NO.6.
[0059] In the present invention, the amino acid sequence shown in SEQ ID NO.1 is specifically: RYWMH; the amino acid sequence shown in SEQ ID NO.2 is specifically: YINPSTGYTEYNQKFRD; the amino acid sequence shown in SEQ ID NO.3 is specifically: PKDDY; the amino acid sequence shown in SEQ ID NO.4 is specifically: SATSSVSSSYLH; the amino acid sequence shown in SEQ ID NO.5 is specifically: GTSNLAS; the amino acid sequence shown in SEQ ID NO.6 is specifically: QQRSGYPLT.
[0060] In the present invention, the amino acid sequence of the heavy chain variable region of the monoclonal antibody is preferably as shown in SEQ ID NO.7; the amino acid sequence of the light chain variable region of the monoclonal antibody is preferably as shown in SEQ ID NO.8.
[0061] In the present invention, the amino acid sequence of the heavy chain variable region (FR1+CDR1+FR2+CDR2+FR3+CDR3+FR4) of the monoclonal antibody is as shown in SEQ ID NO.7, specifically:
[0062] QVQLQQSGAELAKPGASVKMSCKASGYTIN Wlq WVKQRPGQGLEWIG YINPSTGYTE YNQKFRDKATLTADKSSSTAYMQLSSSLTSEDSAVYYCAI PKDDY WGQGTTLTVSS.
[0063] In the present invention, the amino acid sequence of the light chain variable region (FR1+CDR1+FR2+CDR2+FR3+CDR3+FR4) of the monoclonal antibody is as shown in SEQ ID NO.8, specifically:
[0064] ENVLTQSPAIMAASLGEKVPMTC SATSSVSSSYLH WYQQKSGTSPKLWIY GTSNLAS GVPAR FSGSGAGISYSLTISSMEAENDATYYR QQRSGYPLT FGAGTKLELK.
[0065] In the present invention, the monoclonal antibody is preferably prepared by the following method:
[0066] BALB / c mice were intraperitoneally injected with paraffin oil and then with hybridoma cell line 11D8. Ascites was collected after the injection, and the ascites was purified. The obtained broad-spectrum specific monoclonal antibodies against both clofopyralid and clofopyralid isooctyl were cryopreserved.
[0067] In the present invention, the monoclonal antibody described in the above scheme can specifically identify clofopyralid and clofopyralid 2-ethylhexyl ester at the same time. The monoclonal antibody of the present invention can be used to develop a combined immunoassay method for clofopyralid and / or clofopyralid 2-ethylhexyl ester, and to establish a rapid detection method for colloidal gold immunochromatographic test strips, laying a foundation for the research, development and promotion of indirect competitive ELISA kits and colloidal gold test strips.
[0068] The present invention also provides a gene encoding the monoclonal antibody described in the above scheme, wherein the nucleotide sequence of the heavy chain variable region of the gene encoding the monoclonal antibody comprises: a heavy chain variable region CDR1 as shown in SEQ ID NO.9, a heavy chain variable region CDR2 as shown in SEQ ID NO.10, and a heavy chain variable region CDR3 as shown in SEQ ID NO.11; the nucleotide sequence of the light chain variable region of the gene encoding the monoclonal antibody comprises: a light chain variable region CDR1 as shown in SEQ ID NO.12, a light chain variable region CDR2 as shown in SEQ ID NO.13, and a light chain variable region CDR3 as shown in SEQ ID NO.14.
[0069] In the present invention, the nucleotide sequence shown in SEQ ID NO.9 is specifically: aggtactggatgcac ; The nucleotide sequence shown in SEQ ID NO.10 is specifically: tacattaatcctagcactggttatactgagtacaatcagaagttcagg gac ; The nucleotide sequence shown in SEQ ID NO.11 is specifically: cctaaggatgactac ; The nucleotide sequence shown in SEQ ID NO.12 is specifically: agtgccacctcaagtgtaagttccagctacttgcac ; The nucleotide sequence shown in SEQ ID NO.13 is specifically: ggcacatccaacctggcttct ; The nucleotide sequence shown in SEQ ID NO.14 is specifically: cagcagcggagtggttatccgctcacg .
[0070] In the present invention, the gene sequence of the heavy chain variable region of the gene encoding the monoclonal antibody is preferably as shown in SEQ ID NO.15; the gene sequence of the light chain variable region of the gene encoding the monoclonal antibody is preferably as shown in SEQ ID NO.16.
[0071] In the present invention, the nucleotide sequence shown in SEQ ID NO.15 is specifically:
[0072] caggtccaacttcagcagtctggggctgaactggcaaaacctggggcctcagtgaagatgtcctgcaaggcttctggctacaccattaat aggtactggatgcac tgggtaaaacagaggcctggacagggtctggaatggattgga tacattaatcctagcactggttatactgagtacaatcagaagttcagggac aaggccacattgactgcagacaaatcctccagcacagcctacatgcaactgagcagcctgacatctgaggactctgcagtctattactgtgcaatt cc taaggatgactac tggggccaaggcaccactctcacagtctcctca.
[0073] In the present invention, the nucleotide sequence shown in SEQ ID NO.16 is specifically:
[0074] gaaaatgtgctcacccagtctccagcaataatggctgcctctctggggggagaaggtccccatgacctgc agtgccacctcaagtgtaagttccagctacttgcac tggtaccagcagaagtcaggcacttcccccaaactctggatttat ggcacatccaacctggcttct ggagtcccagctcgcttcagtggcagtggggctgggatctcttactctctcacaatcagcagcatggaggctgaaaatgatgcaacttattaccgc cagcagcggagtggttatccgctcacg ttcggtgctgggaccaagctggagctgaaa.
[0075] The present invention also provides a kit or a test strip, comprising the monoclonal antibody described in the above scheme.
[0076] In the present invention, the kit is preferably an indirect competitive ELISA kit; and the test strip is preferably a colloidal gold test strip.
[0077] In the present invention, the kit preferably further comprises an ELISA plate, a coating antigen, a clofopyralid standard, an enzyme-labeled secondary antibody and a substrate reaction solution.
[0078] In the present invention, the enzyme-labeled secondary antibody is preferably goat anti-mouse IgG horseradish peroxide; and the substrate reaction solution is preferably o-phenylenediamine.
[0079] The present invention also provides the use of the hybridoma cell line, the monoclonal antibody, the encoding gene or the kit or test strip described in the above scheme in detecting clofopyralid and / or clofopyralid isooctyl ester.
[0080] In the present invention, the sample to be detected preferably includes food; the detection of clofopyralid and / or clofopyralid 2-ethylhexyl preferably includes detecting the residues of clofopyralid and / or clofopyralid 2-ethylhexyl in food.
[0081] The present invention also provides a method for detecting clofopyralid and / or clofopyralid isooctyl by indirect competitive ELISA, comprising the following steps:
[0082] The sample to be tested is used as the coating antigen and the monoclonal antibody according to any one of claims 2 to 5 is used as the primary antibody to perform indirect competitive ELISA detection.
[0083] The invention provides a method for efficiently and sensitively detecting the residues of fluroxypyraclostrobin and / or fluroxypyraclostrobin, which has important application value.
[0084] The technical scheme of the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, on the basis of the hapten discovered by the present invention or the complete antigen developed by the present method, it is easy for a person skilled in the art to think of using a suitable antibody preparation method to prepare antibodies that are simultaneously resistant to clofopyralid and clofopyralid isooctyl ester, no matter what kind of animal is used for immunization, no matter how the immunization conditions or parameters are set or changed, as long as the hapten discovered by the present invention or the complete antigen developed is used, it belongs to the protection scope of the present invention.
[0085] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0086] Sources of some materials in the examples: sodium bicarbonate, ethanol and dichloromethane were purchased from Beijing Chemical Plant, N,N-diisopropylethylamine (DIPEA) and 3-aminobutyric acid were purchased from Beijing Coupling Technology Co., Ltd.; hydrochloric acid, sodium dihydrogen phosphate dodecahydrate, sodium chloride, gelatin, citric acid monohydrate and Tween-20 were purchased from Sinopharm Chemical Reagent Co., Ltd.; anhydrous N,N-dimethylformamide (DMF) was purchased from Aladdin; 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), Freund's complete adjuvant, Freund's incomplete adjuvant, bovine serum albumin (BSA) and ovalbumin (OVA) were purchased from Sigma; goat anti-mouse IgG-HRP was purchased from Jackson.
[0087] Example 1
[0088] Flupyroxypyr (hapten A) is selected to prepare the activated intermediate of hapten A, and the reaction formula is as follows:
[0089]
[0090] Fluroxypyr (24.34 mg, 0.096 mmol), N-hydroxysuccinimide (NHS, 22.10 mg, 0.192 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, 36.81 mg, 0.237 mmol) were fully dissolved in anhydrous N,N-dimethylformamide (DMF, 2 mL), and reacted with magnetic stirring in a refrigerator at 4°C for 10 h. After the reaction, a product system containing an activated intermediate of hapten A was obtained, which can be directly used for subsequent carrier protein coupling without post-treatment.
[0091] Example 2
[0092] Preparation of fluroxypyrazone and fluroxypyrazone ethyl ester complete antigen C1, the reaction formula is as follows:
[0093]
[0094] Four groups of ovalbumin (OVA) were weighed, 10 mg per group, and the molar ratios (coupling ratios) of OVA to the activated intermediate of hapten A prepared in Example 1 were set to 1:30, 1:40, and 1:50, respectively, and dissolved in phosphate buffer (PBS buffer, pH 7.4, 1 mL) to obtain a carrier protein solution; under stirring, the product system containing the activated intermediate of hapten A prepared in Example 1 was added dropwise to the carrier protein solution, and the reaction was stirred at 25° C. for 4 hours; after the reaction, the obtained product system was washed with PBS buffer (pH 7.4, concentration The solution was dialyzed with pure water for 6 times (pH 7.4, concentration 0.01 mol / L), each dialysis time was 4 h, and a solution containing fluroxypyr and fluroxypyr 2-ethylhexyl complete antigen C1 was obtained. The obtained solutions were dialyzed with pure water and then subjected to MALDI-TOF-MS determination. According to the results, an appropriate solution of fluroxypyr and fluroxypyr 2-ethylhexyl complete antigen C1 was selected and diluted with PBS buffer (pH 7.4, concentration 0.01 mol / L) to a concentration of 1 mg / mL of fluroxypyr and fluroxypyr 2-ethylhexyl complete antigen C1. The obtained dilution was quickly frozen with liquid nitrogen and stored at -20°C for later use.
[0095] Figure 4 This is the MALDI-TOF-MS spectrum of the OVA standard, and the results show that the OVA single-charged ion peak is 44578.958; Figure 1 to Figure 3 The MADLI-TOF-MS spectra of the complete antigen C1 coupled with different feed ratios of cloflupyr and cloflupyr 2-ethylhexyl hapten are shown in Table 1. The results show that the coupling effect of cloflupyr and cloflupyr 2-ethylhexyl hapten with a feed ratio of 40:1 is the best, and the single-charged ion peak is 46717.288. The coupling ratio of carrier protein to hapten = (complete antigen molecular weight - carrier protein molecular weight) / hapten molecular weight. The coupling ratio of complete antigen C1 calculated by this formula is 1:8.38.
[0096] Example 3
[0097] Preparation of fluroxypyrazone and fluroxypyrazone ethyl ester complete antigen C2, the reaction formula is as follows:
[0098]
[0099] Four groups of bovine serum albumin (OVA, 10 mg per group, the molar ratio (coupling ratio) of OVA to the activated intermediate of hapten A prepared in Example 1 was set to 1:30, 1:40, and 1:50, respectively, and dissolved in PBS buffer (pH 7.4, 5 mL) to obtain a carrier protein solution; under stirring, the product system containing the activated intermediate of hapten A prepared in Example 1 prepared in Example 1 was added dropwise to the carrier protein solution, and the reaction was stirred at 25° C. for 4 hours; after the reaction, the obtained product system was washed with PBS buffer (pH 7.4, concentration The 1% chloroquine and 1% chloroquine complete antigen C1 were dialyzed with PBS buffer (pH 7.4, concentration 0.01 mol / L) for 6 times, each dialysis time was 4 h, and a solution containing chloroquine and 1% chloroquine complete antigen C1 was obtained. The obtained solutions were dialyzed with pure water and then subjected to MALDI-TOF-MS determination. According to the results, an appropriate chloroquine and 1% chloroquine complete antigen C1 solution was selected and diluted with PBS buffer (pH 7.4, concentration 0.01 mol / L) to a chloroquine and 1% chloroquine complete antigen C1 concentration of 1 mg / mL. The obtained dilution was quickly frozen with liquid nitrogen and stored at -20°C for later use.
[0100] Figure 8 This is the MALDI-TOF-MS spectrum of the BSA standard, and the results show that the BSA single-charged ion peak is 67208.345; Figure 5 to Figure 7 The MADLI-TOF-MS spectra of the complete antigen C2 coupled with different feed ratios of cloflupyr and cloflupyr 2-ethylhexyl hapten are shown in Table 1. The coupling effect of cloflupyr and cloflupyr 2-ethylhexyl hapten obtained by the hapten feed ratio of 50:1 is the best, and the single-charged ion peak is 74119.262. The coupling ratio of carrier protein to hapten = (complete antigen molecular weight - carrier protein molecular weight) / hapten molecular weight. The coupling ratio of complete antigen C2 calculated by this formula is 1:27.10.
[0101] Table 1 Synthesis results of immunogens and coating sources
[0102]
[0103] ——The MADLI-TOF-MS spectrum has abnormal peaks and the results are not calculated.
[0104] Example 4 Preparation of monoclonal antibodies.
[0105] 1. Immunization of mice.
[0106] (1) 6- to 8-week-old Balb / C mice were used as experimental animals (8-week-old Balb / c mice weighed 23 to 25 g).
[0107] (2) Primary immunization: The diluted clofopyralid and clofopyralid 2-ethylhexyl complete antigen C2 solution (at a concentration of 1 mg / mL) in Example 3 was taken as an immunogen, filtered through a sterile filter, and then an equal volume of Freund's complete adjuvant was added, and the mixture was stirred and emulsified until it did not diffuse when dropped into water, thereby obtaining a clofopyralid and clofopyralid 2-ethylhexyl complete antigen C2 emulsion; the immunization strategy of the clofopyralid and clofopyralid 2-ethylhexyl complete antigen C2 emulsion was to inject 0.05 mg into the peritoneal cavity of mice and 0.05 mg into multiple points of the back subcutaneously, with a total injection dose of 0.1 mg of clofopyralid and clofopyralid 2-ethylhexyl complete antigen C2 emulsion per mouse.
[0108] (3) Reinforced immunization: 2 weeks after the initial immunization, 1 mL of the diluted clofopyralid and clofopyralid 2-ethylhexyl complete antigen C2 solution (at a concentration of 1 mg / mL) prepared in Example 3 was taken, and then an equal volume of Freund's incomplete adjuvant was added, and the mixture was stirred and emulsified until it did not diffuse when dropped into water, thereby obtaining a clofopyralid and clofopyralid 2-ethylhexyl complete antigen C2 emulsion; 0.05 mg of the clofopyralid and clofopyralid 2-ethylhexyl complete antigen C2 emulsion was injected into the peritoneal cavity of mice and 0.05 mg was injected subcutaneously at multiple points on the back of the mice, with a total injection dose of 0.1 mg of the clofopyralid and clofopyralid 2-ethylhexyl complete antigen C2 emulsion per mouse; and the 14-hour booster immunization was repeated every 14 hours. Immunization is performed once a day. Starting from the third booster immunization, blood is collected from the eye sockets of mice 3 days after each immunization to determine the antibody titer and the inhibition rate of cloflupyr and detect the immune performance of the complete antigen. The coated antigen is 1 mg / mL cloflupyr and cloflupyr 2-ethylhexyl complete antigen C1, which is diluted in 4 gradients, namely 1000 times, 2000 times, 4000 times and 8000 times; when the titer is equal to or greater than 1:64000 (the titer is defined as the dilution multiple of the serum when the OD value of the control well is above 1.0), the inhibition rate reaches 50%, indicating that the hapten structure is reasonable, the complete antigen is successfully synthesized, and the immune performance is excellent; it can be used for the preparation of monoclonal antibodies.
[0109] 2. Screening of monoclonal cells.
[0110] (1) Myeloma cell recovery and expansion culture: One week before cell fusion, SP2 / 0 myeloma cells were recovered. After being taken out of the liquid nitrogen tank, the cells were quickly transferred to a 37°C water bath to melt, and then transferred to a centrifuge tube containing preheated DMEM culture medium. After centrifugation and discarding the supernatant, the cells were resuspended and cultured at 37°C and 5% CO2 until the cells grew to a state suitable for fusion.
[0111] (2) Preparation of feeder cells: One day before fusion, feeder cells were collected from the peritoneal cavity of mice of the same strain. After the mice were properly euthanized, the abdomen was carefully cut open using sterile tools, and DMEM culture medium was injected into the peritoneal cavity and collected. The collected cells were centrifuged and resuspended, and then plated in a 96-well culture plate for culture.
[0112] (3) Preparation of splenocytes: 24 h before fusion, stop feeding the mice to reduce peripheral fat. After euthanasia of the mice, collect blood and process the spleen to remove fat and connective tissue, and then disperse the splenocytes in DMEM.
[0113] (4) Cell fusion: Using PEG 2000 as a fusion agent, spleen cells and myeloma cells were mixed in a certain ratio, and the pH value was adjusted before fusion. The fused cells were resuspended in 2% HAT complete culture medium and cultured at 37°C and 5% CO2.
[0114] (5) Screening of specific hybridoma cells: The positivity and specificity of hybridoma cells were detected by icELISA method. First, positive cells were screened by indirect ELISA method, and then the inhibition rate of clofopyralid was detected by indirect competitive ELISA method to screen out highly specific hybridoma cells.
[0115] (6) Cloning of hybridoma cells: Highly specific hybridoma cells are cloned by limiting gradient dilution. The diluted cells are cultured in a 96-well plate with feeder cells, and single clones are screened by microscopic observation and expanded.
[0116] 3. Antibody purification.
[0117] (1) Preparation of monoclonal antibodies: The best monoclonal cell line 11D8 was selected, and ascites antibodies were prepared by the method of preparing ascites tumors in vivo. BALB / c female mice were selected, pretreated with paraffin oil, and then the monoclonal cell suspension was intraperitoneally injected.
[0118] (2) Ascites collection and preliminary processing: After the mouse abdomen is swollen, the ascites is collected and centrifuged, and the clarified liquid is used for subsequent purification.
[0119] (3) Salting-out purification: The salting-out method is used to remove nonspecific impurities in the ascites. First, the ascites is mixed with PBS, saturated ammonium sulfate is added for precipitation, and then the precipitate is dissolved and precipitated again.
[0120] (4) Dialysis and freeze-drying: The purified antibody protein is dialyzed to remove excess salt and impurities, and then vacuum-freeze-dried.
[0121] (5) Antibody storage: The freeze-dried antibody powder was dissolved in PBS, 50% glycerol was added to prepare a 1 mg / mL stock solution, and stored at -20°C.
[0122] 4. Detection of titer and inhibition rate of fusion mice.
[0123] The blood of the fused mice was placed in a 37°C constant temperature incubator for 30 minutes, then placed in a 4°C refrigerator for 2 hours, and then centrifuged in a centrifuge at 4°C and 10,000 r / min for 5 minutes to separate the polyclonal antibody serum of prochlorazine for the following experiments.
[0124] The various buffers used in the following experiments are as follows:
[0125] (1) Coating buffer (pH = 9.6, 0.05 M carbonate buffer): weigh 1.5 g of Na2CO3 and 2.94 g of NaHCO3, and dilute to 1000 mL with ultrapure water;
[0126] (2) Phosphate buffer (0.01 M, pH = 7.4): weigh 0.2 g KH2PO4, 8 g NaCl and 2.92 g NaH2PO4·12H2O, and dilute to 1000 mL with ultrapure water;
[0127] (3) Washing buffer: Add Tween-20 to the prepared phosphate buffer to make the volume fraction of Tween-20 0.1%;
[0128] (4) Sample diluent: Add 10 mL of Tween-20 and 1 g of gelatin to the prepared phosphate buffer, heat in a microwave oven to melt, and dilute to 1 L with ultrapure water;
[0129] (5) Substrate buffer (pH = 5.5): weigh 9.22 g of Na2HPO4·12H2O, 2.55 g of citric acid monohydrate, and 0.5 mL of Tween-20, and dilute to 1 L with ultrapure water;
[0130] (6) Stop solution (2M H2SO4): 445.6 mL of distilled water was measured and 54.4 mL of 98% (volume / volume) concentrated sulfuric acid was added dropwise under stirring.
[0131] 5. Preparation of clofopyralid standard:
[0132] (1) Weigh 10 mg of clofopyralid standard sample and fully dissolve it in 10 mL of methanol to obtain a 1 mg / mL clofopyralid standard stock solution;
[0133] (2) Using the sample diluent, the 1 mg / mL clofopyralid standard stock solution in step (1) is prepared into a clofopyralid standard solution with a final concentration of 1 μg / mL.
[0134] Preparation of clofopyralid coating original solution:
[0135] After the prepared coated complete antigen is freeze-dried, the powder is dissolved in PBS, and 50% glycerol is added to prepare a 1 mg / mL mother solution, which is then gradiently diluted to a suitable concentration for measurement in the mode of 1:1000, 1:2000, and 1:4000.
[0136] Preparation of antiserum and antibody diluent:
[0137] The antiserum prepared in the above steps was diluted with the sample and the antibody stock solution, and the antiserum and the antibody stock solution were graded diluted to the appropriate concentrations for determination in the mode of 1:1000, 1:2000, and 1:4000.
[0138] 6. Checkerboard experiment of antigen and antiserum:
[0139] (1) Coating: Add 100 μL of the coating antigen solution of fluroxypyraclostrobin complete antigen C1 prepared in step 1 to each well of a 96-well ELISA plate, incubate at 37° C. for 3 h, wash three times with washing buffer, and spin dry.
[0140] (2) Competition: Add 50 μL of sample diluent to each control well; add 50 μL of the standard solution of clofopyralid prepared in step 2 to each inhibition well; add the antiserum dilution prepared in step 3 to the ELISA plate (50 μL / well), incubate at 37°C for 30 min, wash the plate three times with washing buffer, and spin dry.
[0141] Add enzyme-labeled secondary antibody: dilute goat anti-mouse enzyme-labeled secondary antibody (IgG-HRP, Jackson) 1000 times, the diluent is 0.1M sample diluent, pH 9.6, add 100 μL to each well, incubate at 37°C for 30 min, wash the plate 3 times with washing buffer, and spin dry.
[0142] (3) Color development: The color development solution was prepared before use. 15-20 mg of o-phenylenediamine (OPD) and 4 μL of 30 wt% hydrogen peroxide were added to every 10 mL of substrate buffer. 100 μL of the resulting mixed solution was added to each well and the color was developed at room temperature in the dark for 15 min.
[0143] (4) Stopping: Add 50 μL of stop solution to each well and measure the OD value of each well at 492 nm using an ELISA reader.
[0144] The calculation formula of inhibition rate is: IR = (CI) / C × 100%, IR represents inhibition rate, I represents inhibition well in ELISA plate, and C represents control well in ELISA plate. The titer of antiserum after the third, fourth and fusion mouse sprint immunization is shown in Table 2.
[0145] Table 2 Serum titer and inhibition rate detection of clofopyralid-resistant mice
[0146]
[0147]
[0148] Note: In Table 2, I represents the inhibition well in the ELISA plate, C represents the control well in the ELISA plate, IR represents the inhibition rate, K represents 1000 times, the coating source concentration is 1 mg / mL, and the inhibition concentration is 1000 ng / mL (clofopyralid).
[0149] The results in Table 2 show that after the fourth immunization, the antiserum inhibition rate was the best, reaching 55.94%, when the coated antigen was diluted 16,000 times and the antibody was diluted 64,000 times, indicating that the complete antigen C2 of fluroxypyra and fluroxypyra isooctyl prepared in Example 3 can be used as an immunogen to prepare anti-fluroxypyra antibodies.
[0150] The titer and inhibition rate of the purified antibodies are shown in Table 3.
[0151] Table 3 Ascites titer and inhibition rate of monoclonal hybridoma 11D8
[0152]
[0153]
[0154] Note: In Table 3, I represents the inhibition well in the ELISA plate, C represents the control well in the ELISA plate, IR represents the inhibition rate, K represents 1000 times, the coating source concentration is 1 mg / mL, and the inhibition concentration is 100 ng / mL (clofopyralid).
[0155] The monoclonal antibody obtained by ascites purification was used to identify the light and heavy chain subtypes of immunoglobulins using mouse monoclonal antibody subtype identification test strips, where the heavy chain subtype was IgG3 and the light chain subtype was κ. Fig. 9According to the subtypes of the light chain and heavy chain of the antibody, the nucleotide sequence and amino acid sequence of the antibody light chain and heavy chain are determined, and the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.7; the amino acid sequence of the light chain variable region of the monoclonal antibody is shown in SEQ ID NO.8. In the present invention, the gene sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.9; the gene sequence of the light chain variable region of the monoclonal antibody is shown in SEQ ID NO.10.
[0156] The optimal coating concentration and antibody dilution concentration were selected, and the concentrations of clofopyralid and clofopyralid 2-ethylhexyl were diluted to 0.001, 0.003, 0.010, 0.030, 0.0915, 0.274, 0.823, 2.469, 7.407, 22.222, 66.667 and 200 ng / mL by gradient dilution method. Then, IC-ELISA was used to detect the IC values of monoclonal antibodies against clofopyralid and clofopyralid. 50 The results were 1.95 ng / mL and 1.36 ng / mL, respectively. The regression curve equation for the detection of flupyr is: Y = 0.099 + 0.940 / (1 + (X / 1.543)) 1.278 , R 2 =0.998; the regression curve equation of fluroxypyr isooctyl ester is: Y=0.052+0.965 / (1+(X / 1.1778)), R 2 =0.997, as Fig.10 Further verification work showed that the cross-reaction rate of the monoclonal antibody to similar pesticides such as picloram, aminopyralid, dicamba and their structurally similar compounds was less than 0.2%. The specific data are shown in Table 4. These results confirm that the monoclonal antibody produced by this cell line is not only highly sensitive, but also highly specific, and can meet the current national regulatory requirements for pesticide residue limit detection.
[0157] Table 4 Specificity detection of fluroxypyraclostrobin 11D8 monoclonal antibody
[0158]
[0159]
[0160] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A hybridoma cell line, It is characterized in that The hybridoma cell line was named 11D8 and deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration with the deposit number: CGMCC No.45937.
2. Use of the hybridoma cell line according to claim 1 in the preparation of a monoclonal antibody that specifically recognizes both clofopyralid and clofopyralid ethyl ester.
3. A monoclonal antibody, It is characterized in that The monoclonal antibody is secreted and produced by the hybridoma cell line or its successive cell line according to claim 1.
4. A monoclonal antibody, It is characterized in that The amino acid sequence of the heavy chain variable region of the monoclonal antibody includes: the heavy chain variable region CDR1 as shown in SEQ ID NO.1, the heavy chain variable region CDR2 as shown in SEQ ID NO.2 and the heavy chain variable region CDR3 as shown in SEQ ID NO.3; the amino acid sequence of the light chain variable region of the monoclonal antibody includes: the light chain variable region CDR1 as shown in SEQ ID NO.4, the light chain variable region CDR2 as shown in SEQ ID NO.5 and the light chain variable region CDR3 as shown in SEQ ID NO.
6.
5. The monoclonal antibody according to claim 4, It is characterized in that The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.7; the amino acid sequence of the light chain variable region of the monoclonal antibody is shown in SEQ ID NO.
8.
6. A gene encoding the monoclonal antibody according to claim 4 or 5, It is characterized in that The nucleotide sequence of the heavy chain variable region of the gene encoding the monoclonal antibody includes: the heavy chain variable region CDR1 as shown in SEQ ID NO.9, the heavy chain variable region CDR2 as shown in SEQ ID NO.10 and the heavy chain variable region CDR3 as shown in SEQ ID NO.11; the nucleotide sequence of the light chain variable region of the gene encoding the monoclonal antibody includes: the light chain variable region CDR1 as shown in SEQ ID NO.12, the light chain variable region CDR2 as shown in SEQ ID NO.13 and the light chain variable region CDR3 as shown in SEQ ID NO.
14.
7. The gene encoding the monoclonal antibody according to claim 6, It is characterized in that The gene sequence of the heavy chain variable region of the gene encoding the monoclonal antibody is shown in SEQ ID NO.15; the gene sequence of the light chain variable region of the gene encoding the monoclonal antibody is shown in SEQ ID NO.
16.
8. A test kit or a test strip, It is characterized in that The monoclonal antibody comprises the monoclonal antibody according to any one of claims 3 to 5.
9. Use of the hybridoma cell line according to claim 1, the monoclonal antibody according to any one of claims 3 to 5, the encoding gene according to claim 6 or 7, or the kit or test strip according to claim 8 in detecting lofluanid and / or lofluanid ethyl ester.
10. A method for detecting clofopyralid and / or clofopyralid 2-ethylhexyl ester by indirect competitive ELISA, It is characterized in that The following steps are involved: The sample to be tested is used as the coating antigen, and the monoclonal antibody according to any one of claims 3 to 5 is used as the primary antibody to perform indirect competitive ELISA detection.
Citation Information
Patent Citations
Hybridoma cell strain AB1 and 2,4,5-trichlorophenoxy acetic acid monoclonal antibody generated thereby
CN107058240A
Praziquantel monoclonal antibody hybridoma cell strain G and application thereof
CN109943535A
